Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy

G. P. Canellos, V. T. DeVita, J. Whang-Peng, B. A. Chabner, P. S. Schein, R. C. Young

研究成果: 雜誌貢獻文章同行評審

56 引文 斯高帕斯(Scopus)

摘要

Thirty two patients in the blastic phase of Philadelphia chromosome positive chronic granulocytic leukemia (CGL) were studied in a prospective randomized trial in which vincristine prednisone (19 patients) was compared with cytosine arabinoside 6 thioguanine (13 patients). Seven remissions (37%), including two complete remissions, were achieved in the vincristine prednisone group. Three of the five with predominant hypodiploid blast cell lines treated with vincristine prednisone had complete or partial remissions. Both complete remitters presented with hypodiploidy consisting of 44 chromosomes. Four patients (30%) who were treated with cytosine arabinoside 6 thioguanine responded with one complete remission. The median survival of the responders was 8 mo, as compared to 1-2 mo for the nonresponders. Crossover to the opposite regimen as secondary therapy following refractoriness or resistance resulted in only 3 partial responses out of 21 treated. All three had previously responded to vincristine prednisone. Of the 32 cases, 14 had an elective splenectomy during the chronic phase of the disease. Prior splenectomy did not influence the response to chemotherapy, as all three complete remitters occurred in the nonsplenectomized group. Similarly, survival in the blastic phase was not affected by prior splenectomy.
原文英語
頁(從 - 到)1003-1009
頁數7
期刊Blood
47
發行號6
出版狀態已發佈 - 十二月 1 1976
對外發佈Yes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

指紋 深入研究「Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy」主題。共同形成了獨特的指紋。

引用此